A total of 917 adult patients in Trials 1 and 2 (16-week trials) and 421 adult patients in Trial 3 (52-week trial) with moderate-to-severe atopic dermatitis not adequately controlled with topical treatments were randomized to DUPIXENT 300 mg Q2W or placebo. For all patients in Trial 3, lesions were treated with concomitant topical corticosteroids (TCS). 1
≥2100
patients
Improvement in lesion extent and severity
Demonstrated safety profile
The Week 52 safety profile of DUPIXENT + TCS was generally consistent with Week 16. The most common adverse reactions (incidence ≥1%) are injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, and dry eye.1